Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors
US10456394B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 15, 2017 |
| Grant date | Oct 29, 2019 |
| Priority date | — |
| Expiry date | Feb 15, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.